Diabetes Drug Actos To Be Advertised In A Big Way In The USA
Local and weekly newspapers throughout the country will feature full-page adverts. The headline will contain the following text׃
"If you have type 2 diabetes, Actos has been shown to lower blood sugar without increasing your risk of having a heart attack or stroke."
Avandia is GlaxoSmikline Plc's second-largest selling drug. The Food and Drug Administration has recently announced that this drug should carry a black-box warning that the risk of heart attacks or chest pains may be elevated for patients taking Avandia.
Ever since May of this year, when news about Avandia's heart attack risk started coming out, sales have plummeted - Actos (Takeda's rival diabetes drug) has done well as a result of Avandia's fall. Many doctors have switched their patients from Avandia to Actos. Before negative news regarding Avandia came out, Avandia and Actos had virtually the same level of US sales.
Both medications belong to the same class of drugs and are indicated for patients with diabetes type 2 - they improve the body's sensitivity to insulin. Actos is the only other marketed medication that works in the same way as Avandia.
Takeda, among other diabetes drug manufacturers, has been asked by the FDA to note in their labels that their diabetes medications have not been proven to lower cardiovascular risk.
Takeda's Actos adverts stress that a major study showed that the drug does not raise heart attack risk or stroke risk in patients.
-- "Avandia Stays On Market With Increased Boxed Warning While Safety Assessed"
Written by׃ Christian Nordqvist
Recommended related news
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Nordqvist, Christian. "Diabetes Drug Actos To Be Advertised In A Big Way In The USA." Medical News Today. MediLexicon, Intl., 17 Nov. 2007. Web.
28 May. 2017. <http://www.medicalnewstoday.com/articles/89134.php>
Nordqvist, C. (2007, November 17). "Diabetes Drug Actos To Be Advertised In A Big Way In The USA." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.